For Doctors in a Hurry
- This prospective study evaluated the forty eight week clinical and laboratory transitions of lebrikizumab treatment in Japanese patients with atopic dermatitis.
- The two center prospective study followed one hundred eighty seven patients stratified by their history of prior systemic therapy use.
- At week forty eight, eighty four percent of systemic therapy naive patients achieved seventy five percent improvement in their eczema severity scores.
- The researchers concluded that lebrikizumab effectively reduced skin lesions and itching, though systemic therapy naive patients showed higher overall response rates.
- Clinicians should note that while lebrikizumab improves head and neck lesions, prior systemic therapy may slightly reduce the treatment response.
Long-Term Management of Refractory Atopic Dermatitis
The therapeutic landscape for moderate-to-severe atopic dermatitis has expanded rapidly with the introduction of biologics and Janus kinase inhibitors, yet achieving sustained disease control remains a challenge for many patients [1, 2]. While interleukin-13 inhibitors like lebrikizumab have demonstrated significant efficacy in randomized controlled trials, clinicians often face the practical hurdle of managing patients who have already cycled through other systemic therapies [3, 4]. These systemic-experienced patients may present with different inflammatory profiles or more recalcitrant disease, particularly in sensitive areas such as the head and neck [5]. Long-term maintenance of clinical response and the normalization of inflammatory biomarkers are critical for improving quality of life and preventing flares [6, 7]. A prospective study now provides 48-week real-world evidence on how prior systemic treatment history influences the longitudinal effectiveness of lebrikizumab, offering clinicians valuable prognostic data for sequencing therapies in refractory cases.
Prospective Real-World Evaluation of IL-13 Inhibition
This two-center prospective study analyzed a cohort of 187 Japanese patients with moderate-to-severe atopic dermatitis to determine the long-term effectiveness of lebrikizumab in a clinical practice setting. Lebrikizumab is an anti-interleukin (IL)-13 antibody that selectively binds to the IL-13 cytokine, blocking a central driver of type 2 skin inflammation. The researchers tracked the 48-week transition of clinical and laboratory indices, providing a longitudinal view of how this biologic performs over a full year of continuous treatment. By monitoring patients for 48 weeks, the study captured the transition from acute response to long-term maintenance, offering data on the durability of the intervention beyond the initial induction phase. To understand how previous treatment history influences current outcomes, the researchers stratified the 187 patients into two distinct groups: those who were systemic therapy-naive and those who were systemic therapy-experienced. This stratification allows clinicians to better anticipate treatment responses based on a patient's prior exposure to systemic immunomodulators or other biologics. The study evaluated several key metrics throughout the 48-week period, including the Eczema Area and Severity Index (EASI, a standard tool for assessing disease extent and severity), the Peak Pruritus Numerical Rating Scale (PP-NRS, a patient-reported measure of maximum itch intensity), and objective laboratory biomarkers. These biomarkers included immunoglobulin E (IgE), lactate dehydrogenase (LDH), and thymus and activation-regulated chemokine (TARC), a specific protein that reflects the activity of T-helper 2 (Th2) cell-mediated inflammation in the skin.
Longitudinal Clinical Response and Pruritus Control
The longitudinal analysis demonstrated that lebrikizumab treatment led to a sustained reduction in the total Eczema Area and Severity Index (EASI) throughout the 48-week study period. This clinical improvement was consistent across different body regions, as the researchers observed a reduction in anatomical site-specific EASI scores over the same timeframe. Furthermore, the biologic provided durable relief from the hallmark symptom of the disease, evidenced by a continuous reduction in the peak pruritus numerical rating scale (PP-NRS). At the 48-week mark, the study identified significant differences in skin clearance based on the patients' prior treatment history. Among the systemic therapy-naive patients, 84% achieved EASI 75 (a 75% or greater improvement in skin symptoms from baseline), while 68.8% of systemic therapy-experienced patients reached this same threshold. The gap between the two cohorts widened when evaluating near-complete skin clearance; 61.8% of systemic therapy-naive patients achieved EASI 90, compared to 41.7% of those who had previously received systemic treatments. For practicing dermatologists and allergists, these numbers suggest that while lebrikizumab is highly effective for both groups, initiating it earlier in the treatment paradigm may yield deeper clinical responses. In contrast to the variations in skin clearance, the impact on pruritus was relatively consistent across both patient populations. The researchers measured the achievement of PP-NRS 4, defined as a clinically meaningful reduction of at least 4 points on the peak pruritus scale. At week 48, the achievement rate for PP-NRS 4 was 79.3% in systemic therapy-naive patients and 75% in systemic therapy-experienced patients. This high rate of itch reduction in both groups underscores the efficacy of IL-13 inhibition in managing the sensory symptoms of atopic dermatitis, even in patients who may not achieve total skin clearance.
Regional Variations and Biomarker Normalization
While lebrikizumab provided broad clinical benefits, the degree of improvement varied slightly by anatomical site and prior treatment history. The researchers observed that the magnitude of decreasing head and neck EASI was slightly lower in systemic therapy-experienced patients compared to those who were systemic-naive. Head and neck dermatitis is notoriously difficult to treat, and this finding helps clinicians set realistic expectations for patients who have already failed other systemic therapies. Despite this regional variation, the study concluded that lebrikizumab showed favorable effectiveness in real-world practice over 48 weeks. This overall success was characterized by higher clinical responses in systemic therapy-naive patients compared with systemic therapy-experienced patients, a trend that remained consistent across all body regions, including in head and neck lesions. Beyond clinical scoring, the study tracked objective laboratory indices to monitor the systemic impact of IL-13 inhibition. The researchers found that lebrikizumab decreased immunoglobulin E (IgE) levels throughout 48 weeks, indicating a sustained reduction in allergic sensitization. Similarly, the treatment led to a continuous decline in lactate dehydrogenase (LDH) levels throughout 48 weeks, a non-specific marker of tissue damage and inflammation. Furthermore, lebrikizumab decreased thymus and activation-regulated chemokine (TARC) levels throughout 48 weeks. Because TARC is a specialized protein that attracts Th2 cells to the skin, its reduction serves as a sensitive indicator of decreasing cutaneous inflammation. For the practicing physician, these biomarker trends confirm that lebrikizumab facilitates a deep molecular normalization that correlates directly with the observed long-term improvements in skin clearance and pruritus.
References
1. Chu A, Wong M, Rayner D, et al. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. Journal of Allergy and Clinical Immunology. 2023. doi:10.1016/j.jaci.2023.08.029
2. Alphonse C, Irfan M, Céspedes SCT, et al. Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review. World Journal of Clinical Cases. 2026. doi:10.12998/wjcc.v14.i12.119171
3. Silverberg JI, Guttman‐Yassky E, Thaçi D, et al. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. New England Journal of Medicine. 2023. doi:10.1056/nejmoa2206714
4. Snast I, Reiter O, Hodak E, Friedland R, Mimouni D, Leshem YA. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis.. American journal of clinical dermatology. 2018. doi:10.1007/s40257-017-0324-7
5. Stevens EM, Vester-Glowinski K, Skov L, Gyldenløve M, Loft N. Effectiveness of Systemic Treatments for Atopic Dermatitis in the Head-and-Neck-Area: A Systematic Review and Meta-analysis.. American journal of clinical dermatology. 2026. doi:10.1007/s40257-026-01013-6
6. Katoh N, Tanaka A, Takahashi H, et al. Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J).. The British journal of dermatology. 2025. doi:10.1093/bjd/ljae394
7. Katoh N, Tanaka A, Takahashi H, et al. Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J).. Current medical research and opinion. 2025. doi:10.1080/03007995.2024.2436982
